This trial compares passive navigation, active navigation and community based screenings to increase prostate cancer screenings in African American men living in Cleveland. The combination of adverse social, behavioral, and institutional circumstances results in severe disparities in prostate cancer incidence, detection, and outcomes. Cancer screenings, including prostate specific antigen (PSA) screening, occur in the context of a primary care visit, however many adult men are not regularly seeing a primary care provider for preventive care. Timely PSA testing is particularly important for African American men as they are diagnosed with prostate cancer at an earlier age and at a more advanced stage than white men.
Additional locations may be listed on ClinicalTrials.gov for NCT05469269.
Locations matching your search criteria
United States
Ohio
Cleveland
Case Comprehensive Cancer CenterStatus: Active
Contact: Erika S. Trapl
Phone: 216-368-0098
PRIMARY OBJECTIVES:
I. Evaluate the effectiveness of three unique interventions on PSA test uptake in African American men and individuals with prostate glands aged 40+.
II. Increase access to primary care physicians and assess uptake of routine primary care.
III. Assess PSA results, intentions to follow-up on recommended care, screening experiences, and trust in screening process.
IV. Identify and understand the needs that support an individual’s success in navigating the process of obtaining PSA screening.
OUTLINE: Participants are randomized in to 1 of 3 arms.
ARM I: Patients receive online education regarding prostate cancer screening via their smartphone. Patients may access a community navigator if they choose.
ARM II: Patients receive online education regarding prostate cancer screening via their smartphone and support from a community navigator.
ARM III: Patients receive online education regarding prostate cancer screening via their smartphone. Patients may access a community navigator to assist them in scheduling attendance at an outreach event.
Patients follow up at 4 months and 14-16 months.
Trial PhaseNo phase specified
Trial Typescreening
Lead OrganizationCase Comprehensive Cancer Center
Principal InvestigatorErika S. Trapl
